HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tetsuhito Kojima Selected Research

Syndecan-4

10/2019Syndecan-4 Inhibits the Development of Pulmonary Fibrosis by Attenuating TGF-β Signaling.
2/2016Syndecan 4 Mediates Nrf2-dependent Expansion of Bronchiolar Progenitors That Protect Against Lung Inflammation.
11/2015Serum Syndecan-4 as a Possible Biomarker in Patients With Acute Pneumonia.
7/2013Molecular mechanisms of syndecan-4 upregulation by TNF-α in the endothelium-like EAhy926 cells.
2/2013The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.
8/2012Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide.
5/2011Syndecan-4 prevents cardiac rupture and dysfunction after myocardial infarction.
5/2011Syndecan-4 deficiency limits neointimal formation after vascular injury by regulating vascular smooth muscle cell proliferation and vascular progenitor cell mobilization.
5/2004Hypoxia induces adhesion molecules on cancer cells: A missing link between Warburg effect and induction of selectin-ligand carbohydrates.
5/2002Syndecan-4 as a molecule involved in defense mechanisms.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tetsuhito Kojima Research Topics

Disease

20Thrombosis (Thrombus)
01/2022 - 04/2002
9Hemorrhage
01/2022 - 08/2002
9Venous Thrombosis (Deep-Vein Thrombosis)
06/2018 - 02/2006
8Thrombophilia
02/2022 - 07/2014
6Leukemia
01/2014 - 03/2002
5Hemophilia A (Haemophilia)
02/2021 - 08/2006
5Inflammation (Inflammations)
10/2019 - 05/2005
4Hemophilia B (Haemophilia B)
01/2022 - 07/2015
4Neoplasms (Cancer)
01/2014 - 05/2004
4Neuroblastoma
06/2012 - 09/2007
3Venous Thromboembolism
06/2019 - 04/2002
3Vascular System Injuries
04/2018 - 04/2004
3Pneumonia (Pneumonitis)
02/2016 - 08/2012
3Colonic Neoplasms (Colon Cancer)
10/2015 - 05/2004
2Protein S Deficiency (Deficiency, Protein S)
02/2022 - 07/2004
2Fibrosis (Cirrhosis)
10/2019 - 02/2004
2Hypoxia (Hypoxemia)
10/2015 - 05/2004
2Infections
02/2013 - 08/2012
2Carcinogenesis
08/2012 - 09/2007
2Breast Neoplasms (Breast Cancer)
06/2012 - 11/2009
2Infarction (Infarctions)
05/2011 - 02/2004
2Myocardial Infarction
05/2011 - 02/2004
2Obesity
05/2005 - 12/2002
1Type 3 von Willebrand Disease
01/2022
1hereditary Thrombophilia
09/2021
1Confusion (Bewilderment)
06/2021
1Inherited Blood Coagulation Disorders
06/2021
1Splenomegaly
02/2021
1Joint Diseases (Joint Disease)
01/2020
1Pulmonary Fibrosis (Fibrosing Alveolitis)
10/2019
1Pulmonary Embolism
06/2018
1Disease Susceptibility (Diathesis)
03/2016
1Lung Diseases (Lung Disease)
02/2016
1Bacterial Pneumonia
11/2015
1Prostatic Neoplasms (Prostate Cancer)
10/2015
1Autoimmune Diseases (Autoimmune Disease)
08/2014
1Necrosis
07/2013
1Chronic Hepatitis C
02/2013
1Graft vs Host Disease (Graft-Versus-Host Disease)
02/2013

Drug/Important Bio-Agent (IBA)

16AntithrombinsIBA
09/2021 - 04/2002
11Proteins (Proteins, Gene)FDA Link
03/2016 - 12/2003
10Syndecan-4IBA
10/2019 - 05/2002
9Prothrombin (Factor II)IBA
06/2018 - 06/2012
8Protein SIBA
02/2022 - 10/2007
8Messenger RNA (mRNA)IBA
01/2022 - 02/2004
6Protein CIBA
09/2021 - 08/2002
5AnticoagulantsIBA
09/2021 - 01/2009
5Factor VIII (Coagulation Factor VIII)IBA
01/2020 - 06/2006
4Factor IX (Coagulation Factor IX)FDA LinkGeneric
01/2022 - 07/2015
4von Willebrand FactorIBA
01/2022 - 04/2004
4EnzymesIBA
10/2015 - 12/2003
4CytokinesIBA
07/2013 - 02/2004
4Tretinoin (Retinoic Acid)FDA LinkGeneric
06/2012 - 03/2002
4Plasminogen Activators (Plasminogen Activator)IBA
05/2005 - 11/2002
4Plasminogen Activator Inhibitor 1IBA
05/2005 - 11/2002
3LigandsIBA
02/2013 - 03/2002
3LipopolysaccharidesIBA
08/2012 - 04/2002
3Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA
06/2012 - 03/2002
2Blood Coagulation Factors (Coagulation Factor)IBA
06/2021 - 03/2016
2Arginine (L-Arginine)FDA Link
06/2018 - 06/2012
2Transcription Factors (Transcription Factor)IBA
10/2015 - 01/2014
2ThrombomodulinIBA
06/2015 - 08/2002
2ThrombinFDA Link
07/2014 - 02/2014
2Pharmaceutical PreparationsIBA
01/2014 - 11/2009
2DNA (Deoxyribonucleic Acid)IBA
01/2014 - 05/2004
2Daunorubicin (Cerubidine)FDA LinkGeneric
01/2014 - 11/2009
2Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA
07/2013 - 05/2011
2Ribavirin (Virazole)FDA LinkGeneric
02/2013 - 01/2013
2Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA
11/2011 - 09/2007
2Factor V (Coagulation Factor V)IBA
04/2010 - 11/2009
2lipoprotein-associated coagulation inhibitor (TFPI)IBA
01/2009 - 08/2002
2sphingosine kinaseIBA
09/2007 - 12/2003
1Cysteine (L-Cysteine)FDA Link
01/2022
1DisulfidesIBA
01/2022
1Glycoproteins (Glycoprotein)IBA
01/2022
1protein S TokushimaIBA
09/2021
1Indicators and Reagents (Reagents)IBA
02/2021
1ErythropoietinFDA Link
02/2021
1Hemoglobins (Hemoglobin)IBA
02/2021
1Chromogenic CompoundsIBA
01/2020
1Bleomycin (Blenoxane)FDA LinkGeneric
10/2019
1CollagenIBA
10/2019
1emicizumabIBA
10/2019
1Combined Oral ContraceptivesIBA
09/2016
1Biomarkers (Surrogate Marker)IBA
11/2015
1Deubiquitinating EnzymesIBA
10/2015
1AndrogensIBA
10/2015
1Glucose (Dextrose)FDA LinkGeneric
10/2015
1Acid CeramidaseIBA
10/2015
1UbiquitinIBA
10/2015
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
10/2015
1Fibrinogen (Factor I)FDA Link
10/2014
1Heparin (Liquaemin)FDA LinkGeneric
02/2014
1DNA Ligase ATPIBA
01/2014
1lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
01/2014
1edoxabanIBA
06/2013
1peginterferon alfa-2b (Pegintron)FDA Link
02/2013

Therapy/Procedure

3Therapeutics
10/2019 - 06/2006
1Perioperative Period
10/2019
1Stem Cell Transplantation
02/2013